Expert Review of Neurotherapeutics最新文献_第8页

Recent advances in understanding the neurobiology of pediatric functional neurological disorder 了解小儿功能性神经紊乱神经生物学的最新进展

IF 4.3 2区医学

Expert Review of Neurotherapeutics Pub Date : 2024-04-09 DOI: 10.1080/14737175.2024.2333390

Kasia Kozlowska, Stephen Scher

引用次数: 0

What role can function magnetic resonance imaging (fMRI) have in guiding therapy for depression? 功能磁共振成像（fMRI）在指导抑郁症治疗方面能发挥什么作用？

IF 4.3 2区医学

Expert Review of Neurotherapeutics Pub Date : 2024-04-09 DOI: 10.1080/14737175.2024.2340998

Drozdstoy S. Stoyanov

引用次数: 0

Profiling lecanemab as a treatment option for Alzheimer’s disease 将莱卡尼单抗作为阿尔茨海默病的治疗方案进行分析

IF 4.3 2区医学

Expert Review of Neurotherapeutics Pub Date : 2024-04-03 DOI: 10.1080/14737175.2024.2333970

Emily R. Schiller, Bret David Silverglate, George T. Grossberg

引用次数: 0

Pharmacological management of gambling disorder: an update of the literature. 赌博障碍的药物治疗：最新文献。

IF 4.3 2区医学

Expert Review of Neurotherapeutics Pub Date : 2024-04-01 Epub Date: 2024-03-01 DOI: 10.1080/14737175.2024.2316833

Gemma Mestre-Bach, Marc N Potenza

{"title":"Pharmacological management of gambling disorder: an update of the literature.","authors":"Gemma Mestre-Bach, Marc N Potenza","doi":"10.1080/14737175.2024.2316833","DOIUrl":"10.1080/14737175.2024.2316833","url":null,"abstract":"Introduction: Gambling disorder (GD) is a mental health condition characterized by persistent and problematic betting behavior. GD generates distress and impairment, and treatment options include psychological and pharmacological interventions.Areas covered: This narrative review explores existing pharmacological treatments for GD. The following classes of medications were considered: opioid-receptor antagonists (e.g. naltrexone and nalmefene), serotonin reuptake inhibitors (e.g. fluvoxamine, paroxetine, sertraline, escitalopram, and citalopram), glutamatergic agents (e.g. N-acetylcysteine (NAC), acamprosate, and memantine), mood stabilizers (e.g. topiramate, carbamazepine, lithium), and other medications (e.g. modafinil, nefazodone, olanzapine, haloperidol, tolcapone, and bupropion).Expert opinion: Due to the limitations of the studies reviewed, solid conclusions regarding the optimal choice of pharmacotherapy for individuals with GD are challenging to draw at this time. Despite some medications, such as naltrexone and nalmefene, showing promising results, efficacy has varied across studies. The review highlights current gaps/limitations, including small sample sizes, limited diversity in participant demographics, the need for exploring different gambling subtypes and treatment responses, high placebo response rates, lack of longer-term longitudinal information, limited investigation of neurobiological correlates and co-occurring disorders, and the importance of implementation research. Further research is needed to address these gaps and explore additional medications, as well as interventions like neuromodulation.","PeriodicalId":12190,"journal":{"name":"Expert Review of Neurotherapeutics","volume":" ","pages":"391-407"},"PeriodicalIF":4.3,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139734799","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

What impact can brain stimulation interventions have on borderline personality disorder? 脑刺激干预对边缘型人格障碍有什么影响？

IF 4.3 2区医学

Expert Review of Neurotherapeutics Pub Date : 2024-04-01 Epub Date: 2024-02-13 DOI: 10.1080/14737175.2024.2316133

Jacopo Lisoni, Gabriele Nibbio, Giulia Baldacci, Andrea Cicale, Andrea Zucchetti, Lorenzo Bertoni, Irene Calzavara Pinton, Nicola Necchini, Giacomo Deste, Stefano Barlati, Antonio Vita

{"title":"What impact can brain stimulation interventions have on borderline personality disorder?","authors":"Jacopo Lisoni, Gabriele Nibbio, Giulia Baldacci, Andrea Cicale, Andrea Zucchetti, Lorenzo Bertoni, Irene Calzavara Pinton, Nicola Necchini, Giacomo Deste, Stefano Barlati, Antonio Vita","doi":"10.1080/14737175.2024.2316133","DOIUrl":"10.1080/14737175.2024.2316133","url":null,"abstract":"Introduction: Borderline personality disorder (BPD) is a severe mental disorder characterized by emotion dysregulation, impulsivity, neuropsychological impairment, and interpersonal instability, presenting with multiple psychiatric comorbidities, functional disability and reduced life expectancy due suicidal behaviors.Areas covered: In this perspective, the authors explore the application of noninvasive brain stimulation (NIBS) (rTMS, tDCS, and MST) in BPD individuals by considering a symptom-based approach, focusing on general BPD psychopathology, impulsivity and neuropsychological impairments, suicidality and depressive/anxious symptoms, and emotion dysregulation.Expert opinion: According to a symptoms-based approach, NIBS interventions (particularly rTMS and tDCS) are promising treatment options for BPD individuals improving core symptoms such as emotional and behavioral dysregulation, neuropsychological impairments and depressive symptoms. However, the heterogeneity of stimulation protocols and of assessment tools used to detect these changes limits the possibility to provide definitive recommendations according to a symptom-based approach. To implement such armamentarium in clinical practice, future NIIBS studies should further consider a lifespan perspective due to clinical variability over time, the role of psychiatric comorbidities affecting BPD individuals and the need to combine NIBS with specialized psychotherapeutic approaches for BPD patients and with functional neuroimaging studies.","PeriodicalId":12190,"journal":{"name":"Expert Review of Neurotherapeutics","volume":" ","pages":"343-360"},"PeriodicalIF":4.3,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139722212","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The impact of exercise on Alzheimer's disease progression. 运动对阿尔茨海默氏症进展的影响。

IF 4.3 2区医学

Expert Review of Neurotherapeutics Pub Date : 2024-04-01 Epub Date: 2024-02-23 DOI: 10.1080/14737175.2024.2319766

Thierry Paillard, Hubert Blain, Pierre Louis Bernard

{"title":"The impact of exercise on Alzheimer's disease progression.","authors":"Thierry Paillard, Hubert Blain, Pierre Louis Bernard","doi":"10.1080/14737175.2024.2319766","DOIUrl":"10.1080/14737175.2024.2319766","url":null,"abstract":"Introduction: The preventive effects of chronic physical exercise (CPE) on Alzheimer's disease (AD) are now admitted by the scientific community. Curative effects of CPE are more disputed, but they deserve to be investigated, since CPE is a natural non-pharmacological alternative for the treatment of AD.Areas covered: In this perspective, the authors discuss the impact of CPE on AD based on an exhaustive literature search using the electronic databases PubMed, ScienceDirect and Google Scholar.Expert opinion: Aerobic exercise alone is probably not the unique solution and needs to be complemented by other exercises (physical activities) to optimize the slowing down of AD. Anaerobic, muscle strength and power, balance/coordination and meditative exercises may also help to slow down the AD progression. However, the scientific evidence does not allow a precise description of the best training program for patients with AD. Influential environmental conditions (e.g. social relations, outdoor or indoor exercise) should also be studied to optimize training programs aimed at slowing down the AD progression.","PeriodicalId":12190,"journal":{"name":"Expert Review of Neurotherapeutics","volume":" ","pages":"333-342"},"PeriodicalIF":4.3,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139930739","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Diagnosing epileptic seizures in patients with Alzheimer's disease and deciding on the appropriate treatment plan. 诊断阿尔茨海默病患者的癫痫发作，并决定适当的治疗方案。

IF 4.3 2区医学

Expert Review of Neurotherapeutics Pub Date : 2024-04-01 Epub Date: 2024-03-01 DOI: 10.1080/14737175.2024.2325038

Francesco Brigo, Simona Lattanzi

{"title":"Diagnosing epileptic seizures in patients with Alzheimer's disease and deciding on the appropriate treatment plan.","authors":"Francesco Brigo, Simona Lattanzi","doi":"10.1080/14737175.2024.2325038","DOIUrl":"10.1080/14737175.2024.2325038","url":null,"abstract":"Introduction: Alzheimer's disease (AD) is the predominant cause of dementia and a significant contributor to morbidity among the elderly. Patients diagnosed with AD face an increased risk of epileptic seizures.Areas covered: Herein, the authors review the challenges in the diagnosis of seizures in patients with AD, the risks of seizures related to medications used in AD and the pharmacological treatment of seizures in AD. The authors also provide the reader with their expert opinion on the subject matter and future perspectives.Expert opinion: Healthcare professionals should maintain a vigilant approach to suspecting seizures in AD patients. Acute symptomatic seizures triggered by metabolic disturbances, infections, toxins, or drug-related factors often have a low risk of recurrence. In such cases, addressing the underlying cause may suffice without initiating antiseizure medications (ASMs). However, unprovoked seizures in certain AD patients carry a higher risk of recurrence over time, warranting the use of ASMs. Although data is limited, both lamotrigine and levetiracetam appear to be reasonable choices for controlling seizures in elderly AD patients. Decisions should be informed by the best available evidence, the treating physician's clinical experience, and the patient's preferences.","PeriodicalId":12190,"journal":{"name":"Expert Review of Neurotherapeutics","volume":" ","pages":"361-370"},"PeriodicalIF":4.3,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139995971","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The latest advances in the pharmacological management of focal epilepsies in children: a narrative review. 儿童局灶性癫痫药物治疗的最新进展：综述。

IF 4.3 2区医学

Expert Review of Neurotherapeutics Pub Date : 2024-04-01 Epub Date: 2024-03-05 DOI: 10.1080/14737175.2024.2326606

Sara Matricardi, Giovanna Scorrano, Giovanni Prezioso, Beatrice Burchiani, Giuseppe Di Cara, Pasquale Striano, Francesco Chiarelli, Alberto Verrotti

{"title":"The latest advances in the pharmacological management of focal epilepsies in children: a narrative review.","authors":"Sara Matricardi, Giovanna Scorrano, Giovanni Prezioso, Beatrice Burchiani, Giuseppe Di Cara, Pasquale Striano, Francesco Chiarelli, Alberto Verrotti","doi":"10.1080/14737175.2024.2326606","DOIUrl":"10.1080/14737175.2024.2326606","url":null,"abstract":"Introduction: Focal epilepsy constitutes the most common epilepsy in children, and medical treatment represents the first-line therapy in this condition. The main goal of medical treatment for children and adolescents with epilepsy is the achievement of seizure freedom or, in drug-resistant epilepsies, a significant seizure reduction, both minimizing antiseizure medications (ASM)-related adverse events, thus improving the patient's quality of life. However, up to 20-40% of pediatric epilepsies are refractory to drug treatments. New ASMs came to light in the pediatric landscape, improving the drug profile compared to that of the preexisting ones. Clinicians should consider several factors during the drug choice process, including patient and medication-specific characteristics.Areas covered: This narrative review aims to summarize the latest evidence on the effectiveness and tolerability of the newest ASMs administered as monotherapy or adjunctive therapy in pediatric epilepsies with focal onset seizures, providing a practical appraisal based on the existing evidence.Expert opinion: The latest ASMs have the potential to be effective in the pharmacological management of focal onset seizures in children, and treatment choice should consider several drug- and epilepsy-related factors. Future treatments should be increasingly personalized and targeted on patient-specific pathways. Future research should focus on discovering new chemical compounds and repurposing medications used for other indications.","PeriodicalId":12190,"journal":{"name":"Expert Review of Neurotherapeutics","volume":" ","pages":"371-381"},"PeriodicalIF":4.3,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140021291","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Evaluating the 6-month formulation of paliperidone palmitate: a twice-yearly injectable treatment for schizophrenia in adults. 评估帕利哌酮棕榈酸酯的 6 个月制剂：一种每年注射两次的成人精神分裂症治疗药物。

IF 4.3 2区医学

Expert Review of Neurotherapeutics Pub Date : 2024-04-01 Epub Date: 2024-03-06 DOI: 10.1080/14737175.2024.2325655

Giovanna Cirnigliaro, Vera Battini, Michele Castiglioni, Marica Renne, Giulia Mosini, Stefania Cheli, Carla Carnovale, Bernardo Dell'Osso

{"title":"Evaluating the 6-month formulation of paliperidone palmitate: a twice-yearly injectable treatment for schizophrenia in adults.","authors":"Giovanna Cirnigliaro, Vera Battini, Michele Castiglioni, Marica Renne, Giulia Mosini, Stefania Cheli, Carla Carnovale, Bernardo Dell'Osso","doi":"10.1080/14737175.2024.2325655","DOIUrl":"10.1080/14737175.2024.2325655","url":null,"abstract":"Introduction: Paliperidone Palmitate is the only antipsychotic that has been developed in three different intramuscular long-acting injectable (LAI) dosing regimen: monthly (PP1M), quarterly (PP3M), and from 2020 also twice-yearly (PP6M). The latter was approved for the maintenance treatment of adults with schizophrenia and clinically stabilized with PP1M or PP3M.Areas covered: Data from studies evaluating efficacy in the maintenance treatment of schizophrenia with PP6M are reviewed. Since no post-marketing safety studies are currently available, data from spontaneous reporting system databases, FAERS and Eudravigilance, are analyzed and the reported treatment-emergent adverse events of PP6M are discussed.Expert opinion: The efficacy of PP6M is comparable to that of PP3M in terms of relapses prevention in patients with schizophrenia previously stabilized on PP3M or PP1M. Also, the maintenance of clinical efficacy in the long term has been demonstrated. Data from pharmacovigilance analyses, as well as from phase 3 studies, show that PP6M is generally well tolerated, consistently with PP3M safety data. PP6M allows a longer dosing interval than any other LAI antipsychotics, potentially reducing nonadherence and disease relapses. In future, an increase in the prescription rates of PP6M is expected and real-world efficacy and tolerability studies will be conducted.","PeriodicalId":12190,"journal":{"name":"Expert Review of Neurotherapeutics","volume":" ","pages":"325-332"},"PeriodicalIF":4.3,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140039061","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A review of amphetamine extended release once-daily options for the management of attention-deficit hyperactivity disorder. 安非他明缓释剂每日一次治疗注意缺陷多动障碍方案综述。

IF 4.3 2区医学

Expert Review of Neurotherapeutics Pub Date : 2024-04-01 Epub Date: 2024-02-23 DOI: 10.1080/14737175.2024.2321921

Kendall Abbas, Elizabeth W Barnhardt, Patricia L Nash, Maria Streng, Daniel L Coury

{"title":"A review of amphetamine extended release once-daily options for the management of attention-deficit hyperactivity disorder.","authors":"Kendall Abbas, Elizabeth W Barnhardt, Patricia L Nash, Maria Streng, Daniel L Coury","doi":"10.1080/14737175.2024.2321921","DOIUrl":"10.1080/14737175.2024.2321921","url":null,"abstract":"Introduction: Amphetamine preparations are one of the two categories of stimulant medications approved for the treatment of attention deficit hyperactivity disorder (ADHD). Optimal treatment of ADHD aims to reduce core symptoms for as much of the waking hours as possible, leading to longer-acting delivery formats. In addition, the pediatric population commonly has difficulty swallowing pills and manufacturers have developed a variety of options to facilitate this concern. These include chewable tablets, capsules that may be sprinkled on soft food, liquids and transdermal patches.Areas covered: This article reviews the once-daily extended-release preparations currently available for amphetamine compounds, their pharmacodynamics, and common adverse effects.Expert opinion: There is an extensive evidence base supporting use of amphetamine preparations in the treatment of ADHD. Rapid onset of action and a favorable side effect profile make these widely used. The availability of once-daily extended-release chewable tablets, capsules that can be opened and sprinkled, and liquid formulations provides clinicians with multiple options to meet the specific needs of patients with difficulty swallowing whole pills.","PeriodicalId":12190,"journal":{"name":"Expert Review of Neurotherapeutics","volume":" ","pages":"421-432"},"PeriodicalIF":4.3,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139930738","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0